Behavioural And Microbial Risk Factors Associated With Bacterial Vaginosis In Young Women
Funder
National Health and Medical Research Council
Funding Amount
$290,032.00
Summary
Bacterial vaginosis (BV) is one of the commonest genital infections in women of reproductive age. Few data have determined the incidence of BV among young low risk women and the associated risk factors. This study aims to establish the incidence of BV in a cohort of young women and determine if BV is sexually transmitted. We hope this research will led to improvements in management and treatment of BV.
Optimising Large-scale Public Health Interventions To Control Neglected Tropical Diseases
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Neglected tropical diseases (NTD) are a group of health conditions that affect the poorest of the poor, particularly in remote and rural areas. They affect the most vulnerable communities and cause substantial, chronic health harms impairing personal and social development. Several debilitating NTD are common in remote indigenous communities and Pacific islands. I propose a series of studies to investigate new strategies to control NTD in large populations where these diseases are endemic.
Investigation Of Candidate Aetiologic Organisms Of Bacterial Vaginosis In Diverse And Unique Epidemiological And Clinical Studies
Funder
National Health and Medical Research Council
Funding Amount
$564,438.00
Summary
Bacterial vaginosis (BV), a vaginal infection affecting 10% of Australian women, is an important cause of premature birth, yet its cause is unknown. We are conducting studies to understand the cause of BV in order to improve diagnosis and treatment.
Genetic Associations Of Early Retinal Pathologic Phenotypes: Data Pooling And Meta-analyses Of Multiple Populations
Funder
National Health and Medical Research Council
Funding Amount
$736,481.00
Summary
We aim to use data already collected from multiple population-based studies to investigate the likely pathogeneses of early retinal phenotypes that are either markers for cardiovascular risk or precursors of a blinding condition. Understanding if there are genetic susceptibilities for these phenotypes, and if so, how they together with environmental exposures jointly influence the occurrence of the diseases may be key to reduce the burden from cardiovascular disease and blindness.
MULTICENTRE BRONCHIECTASIS STUDY: A Collaborative And International Study Of Bronchiectasis In Indigenous Children.
Funder
National Health and Medical Research Council
Funding Amount
$1,496,414.00
Summary
Aboriginal children have repeated pneumonia episodes; some get better while others develop bronchiectasis (a chronic lung disease). The risk factors associated with progression to bronchiectasis, and the natural history of bronchiectasis in this population is little known. Given the similarities of these diseases among indigenous populations of affluent countries and to increase study size, a collaborative and international study of Indigenous children (Aboriginal and Torres Strait Islander, New ....Aboriginal children have repeated pneumonia episodes; some get better while others develop bronchiectasis (a chronic lung disease). The risk factors associated with progression to bronchiectasis, and the natural history of bronchiectasis in this population is little known. Given the similarities of these diseases among indigenous populations of affluent countries and to increase study size, a collaborative and international study of Indigenous children (Aboriginal and Torres Strait Islander, New Zealand Maori or Pacific Islander and Alaskan Native) has been initiated. In Indigenous children, we aim to define the natural history of chronic moist cough (those at risk of developing bronchiectasis) and bronchiectasis, identify the risk factors associated with progression from early-mild disease (chronic moist cough) to bronchiectasis and to define the role of continuous antibiotic treatment in the prevention of recurrent pulmonary infections that are very common in these children. We plan to follow up Aboriginal children aged 12 months to 8 years diagnosed with bronchiectasis or chronic moist cough. For those diagnosed with bronchiectasis, after fully informed consent is obtained from the parent(s), the child will be allocated by chance to one of the 2 treatment regimes: (1) Azithromycin once-week or (2) placebo once-week. Children will receive the medication or the placebo for a period of 24 months. All these children will be clinically seen 2x-year by the study's paediatrician and 2x-year by the research nurse for the duration of the study. By documenting, for the first time, the epidemiology and natural history of children with chronic moist cough and bronchiectasis, the study will provide a much-needed rationale for their management. If we can scientifically show that this is true, that Azithromycin is effective in reducing the number of respiratory infections, this would be an achievable advance in the treatment in the field for these children.Read moreRead less